Glenmark and BeiGene partner to market cancer drugs in India EP News Bureau May 21, 2024 Both the companies enter into an agreement for marketing and distribution of Tislelizumab and Zanubrutinib in India
Novartis’s tislelizumab phase-III trial data shows survival results in esophageal cancer EP News Bureau Jul 5, 2022 First-line tislelizumab plus chemotherapy showed median Overall Survival (OS) of 17.2 months versus 10.6 months for chemotherapy…
